{"result": "(\"entity\"<|>DIABETES<|>EVENT<|>Diabetes is a chronic health condition that affects how the body processes blood sugar (glucose) and is often a focus of obesity surgery outcomes.)\n##\n(\"entity\"<|>HEART ATTACK<|>EVENT<|>Heart attack, also known as myocardial infarction, is a serious medical condition that can be reduced by bariatric surgery according to recent studies.)\n##\n(\"entity\"<|>STROKE<|>EVENT<|>Stroke is a medical condition that is not significantly reduced by bariatric surgery, as indicated in the studies referenced.)\n##\n(\"entity\"<|>OBESITY<|>EVENT<|>Obesity is a medical condition characterized by excess body fat, often treated through surgical procedures like bariatric surgery.)\n##\n(\"entity\"<|>CARDIOVASCULAR DISEASE<|>EVENT<|>Cardiovascular disease encompasses a range of heart and blood vessel disorders, which can be impacted by obesity and its surgical treatments.)\n##\n(\"entity\"<|>MORTALITY<|>EVENT<|>Mortality refers to the incidence of death, which can be influenced by obesity and its surgical interventions.)\n##\n(\"entity\"<|>GASTRIC BYPASS<|>EVENT<|>Gastric bypass is a type of bariatric surgery that helps patients lose weight and improve related health conditions.)\n##\n(\"entity\"<|>ENDOSCOPIC SLEEVE GASTROPLASTY<|>EVENT<|>Endoscopic sleeve gastroplasty is a minimally invasive weight-loss procedure that is part of the research on obesity surgery.)\n##\n(\"entity\"<|>BIOENTERICS INTRAGASTRIC BALLOON<|>EVENT<|>The BioEnterics intragastric balloon is a device used in weight loss procedures, referenced in studies on obesity treatment.)\n##\n(\"entity\"<|>HAZARD RATIO<|>EVENT<|>Hazard ratio is a statistical measure used in studies to compare the risk of an event occurring between two groups, often used in medical research.)\n##\n(\"entity\"<|>COMORBIDITIES<|>EVENT<|>Comorbidities refer to the presence of one or more additional conditions co-occurring with a primary condition, often discussed in the context of obesity and diabetes.)\n##\n(\"relationship\"<|>DIABETES<|>BARIATRIC SURGERY<|>Bariatric surgery is often performed to improve diabetes control in patients with obesity.<|>8)\n##\n(\"relationship\"<|>HEART ATTACK<|>BARIATRIC SURGERY<|>Bariatric surgery has been shown to reduce the risk of heart attacks in patients with obesity.<|>7)\n##\n(\"relationship\"<|>STROKE<|>BARIATRIC SURGERY<|>Studies indicate that bariatric surgery does not significantly reduce the risk of stroke in patients.<|>3)\n##\n(\"relationship\"<|>OBESITY<|>BARIATRIC SURGERY<|>Bariatric surgery is a common treatment for obesity, aimed at weight loss and health improvement.<|>9)\n##\n(\"relationship\"<|>CARDIOVASCULAR DISEASE<|>BARIATRIC SURGERY<|>Bariatric surgery can have a positive impact on reducing the risk of cardiovascular disease in obese patients.<|>6)\n##\n(\"relationship\"<|>MORTALITY<|>BARIATRIC SURGERY<|>Bariatric surgery has been associated with reduced overall mortality rates in patients with severe obesity.<|>7)\n##\n(\"relationship\"<|>GASTRIC BYPASS<|>BARIATRIC SURGERY<|>Gastric bypass is a specific type of bariatric surgery aimed at weight loss and health improvement.<|>8)\n##\n(\"relationship\"<|>ENDOSCOPIC SLEEVE GASTROPLASTY<|>BARIATRIC SURGERY<|>Endoscopic sleeve gastroplasty is another method of bariatric surgery that is gaining attention for its effectiveness.<|>7)\n##\n(\"relationship\"<|>BIOENTERICS INTRAGASTRIC BALLOON<|>BARIATRIC SURGERY<|>The BioEnterics intragastric balloon is a tool used in bariatric surgery to assist with weight loss.<|>6)\n##\n(\"relationship\"<|>HAZARD RATIO<|>BARIATRIC SURGERY<|>Hazard ratios are often used in studies to evaluate the effectiveness of bariatric surgery on various health outcomes.<|>5)\n##\n(\"relationship\"<|>COMORBIDITIES<|>BARIATRIC SURGERY<|>Bariatric surgery is often performed to address comorbidities associated with obesity, such as diabetes and hypertension.<|>8)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: estinales que, en el caso de la diabetes, incluso puede                                                                                                           (IC 95% 0,46-0,64)                       (IC 95% 0,41-0,70)                      (IC 95% 0,32-0,75)  (IC 95% 0,35-0,64)\n                                                                                                                                                                                  0,5                                                                                     (IC 95% 0,30-0,69)\n         mejorar el control glucémico. La pérdida de un 15% de peso durante el año que suele dejar-                                                                                                                0,54                                    0,54\n                                                                                                                                                                                  0,4                                                                                          0,46                0,49                 0,48\n         se implantado se acompaña de una disminución de 1% de HbA1c, pero como debe retirarse                                                                                            (IC 95% 0,26-0,41)                      (IC 95% 0,22-0,46)\n         a los 12 meses, los pacientes vuelven a su situación inicial. Es una técnica no exenta de                                                                                0,3          0,33                                    0,33\n         complicaciones.                Y no se plantea como un procedimiento para utilizar antes de una cirugía                                                                  0,2\n         bariátrica.                                                                                                                                                              0,1\n                                                                                                                                                                                    0\n         Referencias:                                                                                                                                                                          DM2                 HTA             Dislipidemia            IAM                 Ictus           Eventos CV          Mortalidad\n         •  López-Nava G, Bautista-Castaño I, Jimenez A, de Grado T, Fernandez-Corbelle JP. The Primary Obesity Surgery Endolumenal (POSE)\n            procedure: one-year patient weight loss and safety outcomes. Surg Obes Relat Dis. 2015;11(4):861-5.\n         •  Lopez-Nava G, Rubio MA, Prados S, Pastor G, Cruz MR, Companioni E, et al. BioEnterics® intragastric balloon (BIB®). Single ambula-                           Figura 10. Hazard-ratio (intervalo de confianza [IC] 95% al 95%) de mejoría de comorbilida-\n            tory center Spanish experience with 714 consecutive patients treated with one or two consecutive balloons. Obes Surg. 2011;21(1):\n            5-9.                                                                                                                                                         des, eventos cardiovasculares y mortalidad en sujetos con cirugía bariátrica a largo plazo.\n         •  Lopez-Nava G, Sharaiha RZ, Vargas EJ, Bazerbachi F, Manoel GN, Bautista-Castaño I, et al. Endoscopic Sleeve Gastroplasty for Obesity:                        Basado en Kwok CS et al. Int J Cardiol. 2014;173(1):20-8.\n            a Multicenter Study of 248 Patients with 24 Months Follow-Up. Obes Surg. 2017;27(10):2649-55.\n         •  Vilarrasa N, de Gordejuela AG, Casajoana A, Duran X, Toro S, Espinet E, et al. Endobarrier® in Grade I Obese Patients with Long-\n            Standing Type 2 Diabetes: Role of Gastrointestinal Hormones in Glucose Metabolism. Obes Surg. 2017;27(3):569-77.                                             Referencias:\n                                                                                                                                                                         • Eliasson B, Liakopoulos V, Franzén S, Näslund I, Svensson AM, Ottosson J, et al. Cardiovascular disease and mortality in patients with\n                                                                                                                                                                           type 2 diabetes after bariatric surgery in Sweden: a nationwide, matched, observational cohort study. Lancet Diabetes Endocrinol.\n                                                                                                                                                                           2015;3(11):847-54.\n         A   la vista de los últimos metaanálisis, ¿cuáles serían las expectativas razonables                                                                            • Fisher DP, Johnson E, Haneuse S, Arterburn D, Coleman KJ, O’Connor PJ, et al. Association Between Bariatric Surgery and\n     21                                                                                                                                                                    Macrovascular Disease Outcomes in Patients With Type 2 Diabetes and Severe Obesity. JAMA. 2018;320(15):1570-82.\n         del paciente ante la cirugía bariátrica?                                                                                                                        • Kwok CS, Pradhan A, Khan MA, Anderson SG, Keavney BD, Myint PK, et al. Bariatric surgery and its impact on cardiovascular disease\n                                                                                                                                                                           and mortality: a systematic review and meta-analysis. Int J Cardiol. 2014;173(1):20-8.\n                                                                                                                                                                         • Sjöström L, Peltonen M, Jacobson P, Sjöström CD, Karason K, Wedel H, et al. Bariatric surgery and long-term cardiovascular events.\n         A.   Se reduce el riesgo de infarto agudo de miocardio, pero no de ictus.                                                                                         JAMA. 2012;307(1):56-65.\n         B.   Consigue reducir la mortalidad total.\n         C. En su caso, la opción que con más posibilidades le ayudaría a remitir su diabetes,                                                                           Respecto al             bypass gástrico como                        técnica quirúrgica                  para el tratamiento\n              hipertensión y microalbuminuria sería la gastrectomía tubular.\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>LOPEZ-NAVA G<|>PERSON<|>López-Nava G is an author of multiple studies related to obesity surgery and its outcomes.)\n##\n(\"entity\"<|>BAUTISTA-CASTAÑO I<|>PERSON<|>Bautista-Castaño I is a co-author of studies on obesity surgery and its effects on patients.)\n##\n(\"entity\"<|>JIMENEZ A<|>PERSON<|>Jimenez A is a researcher involved in studies regarding obesity surgery outcomes.)\n##\n(\"entity\"<|>DE GRADO T<|>PERSON<|>De Grado T is a contributor to research on the Primary Obesity Surgery Endolumenal (POSE) procedure.)\n##\n(\"entity\"<|>FERNANDEZ-CORBELLE JP<|>PERSON<|>Fernandez-Corbelle JP is a co-author of studies on obesity surgery and patient outcomes.)\n##\n(\"entity\"<|>POSE<|>EVENT<|>The Primary Obesity Surgery Endolumenal (POSE) procedure is a surgical technique aimed at weight loss and improving diabetes control.)\n##\n(\"entity\"<|>BARIATRIC SURGERY<|>EVENT<|>Bariatric surgery refers to various surgical procedures performed on the stomach or intestines to induce weight loss.)\n##\n(\"entity\"<|>SWEDEN<|>GEO<|>Sweden is a country where significant research on bariatric surgery and its effects on cardiovascular disease has been conducted.)\n##\n(\"entity\"<|>JAMA<|>ORGANIZATION<|>JAMA is a medical journal that publishes research studies, including those on bariatric surgery and diabetes outcomes.)\n##\n(\"entity\"<|>LANCET DIABETES ENDOCRINOL<|>ORGANIZATION<|>Lancet Diabetes Endocrinol is a journal that publishes studies related to diabetes and its complications.)\n##\n(\"relationship\"<|>LOPEZ-NAVA G<|>POSE<|>López-Nava G is a researcher involved in the study of the POSE procedure and its outcomes.<|>8)\n##\n(\"relationship\"<|>BAUTISTA-CASTAÑO I<|>POSE<|>Bautista-Castaño I contributed to the research on the POSE procedure and its effectiveness.<|>8)\n##\n(\"relationship\"<|>JIMENEZ A<|>POSE<|>Jimenez A is a co-author of studies related to the POSE procedure, indicating involvement in its research.<|>8)\n##\n(\"relationship\"<|>DE GRADO T<|>POSE<|>De Grado T is involved in the research of the POSE procedure, contributing to its findings.<|>8)\n##\n(\"relationship\"<|>FERNANDEZ-CORBELLE JP<|>POSE<|>Fernandez-Corbelle JP is a co-author of studies on the POSE procedure, indicating his involvement in the research.<|>8)\n##\n(\"relationship\"<|>LOPEZ-NAVA G<|>BARIATRIC SURGERY<|>López-Nava G's research includes studies on bariatric surgery and its effects on patients.<|>7)\n##\n(\"relationship\"<|>BAUTISTA-CASTAÑO I<|>BARIATRIC SURGERY<|>Bautista-Castaño I's work includes research on bariatric surgery outcomes.<|>7)\n##\n(\"relationship\"<|>JIMENEZ A<|>BARIATRIC SURGERY<|>Jimenez A has contributed to studies on bariatric surgery and its implications for patients.<|>7)\n##\n(\"relationship\"<|>DE GRADO T<|>BARIATRIC SURGERY<|>De Grado T's research includes aspects of bariatric surgery and its effects on health.<|>7)\n##\n(\"relationship\"<|>FERNANDEZ-CORBELLE JP<|>BARIATRIC SURGERY<|>Fernandez-Corbelle JP has co-authored studies on bariatric surgery, indicating his involvement in this field.<|>7)\n##\n(\"relationship\"<|>SWEDEN<|>BARIATRIC SURGERY<|>Sweden is the location of significant research on bariatric surgery and its outcomes.<|>6)\n##\n(\"relationship\"<|>LOPEZ-NAVA G<|>JAMA<|>López-Nava G has published research in JAMA regarding obesity surgery outcomes.<|>5)\n##\n(\"relationship\"<|>BAUTISTA-CASTAÑO I<|>JAMA<|>Bautista-Castaño I has contributed to research published in JAMA on obesity surgery.<|>5)\n##\n(\"relationship\"<|>JIMENEZ A<|>JAMA<|>Jimenez A's research has been published in JAMA, focusing on obesity surgery outcomes.<|>5)\n##\n(\"relationship\"<|>DE GRADO T<|>JAMA<|>De Grado T has co-authored studies in JAMA related to obesity surgery.<|>5)\n##\n(\"relationship\"<|>FERNANDEZ-CORBELLE JP<|>JAMA<|>Fernandez-Corbelle JP has published research in JAMA regarding obesity surgery outcomes.<|>5)\n##\n(\"relationship\"<|>SWEDEN<|>LANCET DIABETES ENDOCRINOL<|>Research on bariatric surgery and diabetes outcomes has been published in Lancet Diabetes Endocrinol, including studies from Sweden.<|>4)\n##\n(\"relationship\"<|>LOPEZ-NAVA G<|>LANCET DIABETES ENDOCRINOL<|>López-Nava G has contributed to studies published in Lancet Diabetes Endocrinol regarding obesity surgery and diabetes.<|>4)\n##\n(\"relationship\"<|>BAUTISTA-CASTAÑO I<|>LANCET DIABETES ENDOCRINOL<|>Bautista-Castaño I has co-authored studies in Lancet Diabetes Endocrinol related to obesity surgery.<|>4)\n##\n(\"relationship\"<|>JIMENEZ A<|>LANCET DIABETES ENDOCRINOL<|>Jimenez A's research has been published in Lancet Diabetes Endocrinol, focusing on obesity surgery outcomes.<|>4)\n##\n(\"relationship\"<|>DE GRADO T<|>LANCET DIABETES ENDOCRINOL<|>De Grado T has co-authored studies in Lancet Diabetes Endocrinol regarding obesity surgery.<|>4)\n##\n(\"relationship\"<|>FERNANDEZ-CORBELLE JP<|>LANCET DIABETES ENDOCRINOL<|>Fernandez-Corbelle JP has published research in Lancet Diabetes Endocrinol regarding obesity surgery outcomes.<|>4)\n<|COMPLETE|>"}]}